Brewed for scale: EvodiaBio ferments US$6.6 million backing to take Danish aroma tech global

Danish flavor biotechnology company EvodiaBio secured €6 million (US$6.6 million) in a new funding round led by USA-based life sciences investor RA Capital, as the company prepared to scale its fermentation platform globally.

The round included continued backing from existing investor EIFO, alongside new international participants Wild Radicals and Francis Family Funds. EvodiaBio reported that the capital would be used to accelerate growth across Europe, the United States, and Canada, with expansion into Asia identified as the next strategic step.

Founded as a research project, EvodiaBio has developed a fermentation-based technology platform for producing volatile aroma molecules at industrial scale. The company said its approach offers a more efficient and sustainable alternative to traditional aroma production methods, with initial commercial traction in the beer industry and broader applications across beverages and flavors.

“This investment puts us in a position to scale globally,” said Camilla Kloss Fenneberg, CEO of EvodiaBio. “Within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the biotech industry. This investment enables us to accelerate global growth and realize our ambition of becoming a Danish unicorn in industrial biotech.”

EvodiaBio reported that it has already removed key technological and commercial risks, moving from laboratory development to full industrial production with documented market demand. The company described the latest raise as a turning point from validation toward international scaling.

Since launching its first commercial products earlier in 2025, EvodiaBio has worked with more than 70 commercial beer brews and engaged in over 10 projects with top-40 breweries worldwide. The company said its technology could reduce reliance on hops, a crop increasingly affected by climate volatility, while maintaining flavor consistency and quality.

RA Capital cited EvodiaBio’s execution speed and early commercial maturity as key drivers behind the investment. “EvodiaBio has developed a technology platform that convincingly solves one of the most complex problems in the aroma and beverage industries, how to efficiently and sustainably produce natural aromas at industrial scale,” said Kyle Teamey, Managing Partner at RA Capital. “The team has executed with a speed and quality rarely seen in biotech, and we see enormous global potential.”

EvodiaBio Chairman Jarne Elleholm said the company’s progress stood out even within a sector known for long development cycles.

“What EvodiaBio has achieved in record time is highly unusual in our industry,” he said. “Moving from the laboratory to a complete production platform, global partnerships, and market interest in such a short time demonstrates that Denmark has the potential to become a leading hub for biosolutions.”

Looking ahead, EvodiaBio reported plans to expand its technology into additional beverage categories, including wine, and into the wider aroma industry. Asia has been identified as a priority growth region as the company builds on existing partnerships with Symrise and Lallemand to accelerate market access.

“This investment places us in a strong position to accelerate our growth and expand our technology into new markets, especially in Asia,” Fenneberg said. “We have achieved strong commercial validation, but we are still early in our growth journey.”

The latest raise marked EvodiaBio’s third funding round in three years, bringing total capital raised to DKK 150 million (approximately US$22 million).